Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 30,763 articles published since 2009
|||| 45 

These are the 30763 published articles about Pancreatic Neoplasms that originated from Worldwide during 2009-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
451 Editorial Pain in pancreatic cancer: does drug treatment still play a role? 2011

Uomo, Ilaria. · ·JOP · Pubmed #21904067.

ABSTRACT: -- No abstract --

452 Editorial Use of predictive markers in oncology: are phase 3 trials always required? 2011

Markman, Maurie. · ·Oncology · Pubmed #21894048.

ABSTRACT: -- No abstract --

453 Editorial [Pancreatoduodenectomy--past, present and future]. 2011

Popescu, I / Dumitraşcu, T. · ·Chirurgia (Bucur) · Pubmed #21853734.

ABSTRACT: Pancreatico-duodenectomy represents one of the most important and complex surgical digestive procedure. Although rarely performed in the past, nowadays has become a routine surgery. Moreover, postoperative mortality significantly decreased (from over 30% to less than 5%), while the number of severe, life-threatening complications were reduced. This outcome was possible due to technical innovations acquired in time, and also due to a better per operative management of these patients, in tertiary surgical centers, with experienced operative teams. Some modifications of the standard procedure of resection, like posterior or artery first approach contributed to better results, facilitating en-block resection of the portal/ superior mesenteric vein, where needed. Moreover, posterior approach facilitates complete mesopancreas excision, involved in local recurrence after resection of pancreatic head adenocarcinoma. Regarding reconstruction after pancreaticoduodenectomy, there is no optimal type of anastomosis (pancreatico-gastrostomy vs pancreatico-jejunostomy), results being related mostly with the expertise of the operative team, as like the postoperative pancreatic fistula rate. Future studies are deemed to look on the real clinical impact of the total mesopancreas excision in achieving negative resection margins, decreasing local recurrence and increasing the long-term survival of patients resected for pancreatic head cancer.

454 Editorial Pancreatic neoplasm in 2011: an update. 2011

Saif, Muhammad Wasif. · ·JOP · Pubmed #21737886.

ABSTRACT: Pancreatic cancer still is a significant, unresolved therapeutic challenge with nearly similar incidence and mortality rates. It is the most lethal type of digestive cancer with a 5-year survival rate of 5%. Adjuvant chemotherapy remains to be gemcitabine alone or combined with infusional 5-fluorouracil with radiation therapy. Nevertheless, only a few patients survive for at least 5 years after R0 resection and adjuvant therapy. Most patients need palliative treatment. Once pancreatic cancer becomes metastatic, it is uniformly fatal with an overall survival of typically 6 months from diagnosis. Chemotherapy is an important component of palliative care but must be administered as a part of a multidisciplinary approach, including palliation of pain, managing weight loss, and deterioration in functional status. Gemcitabine has been the standard in both locally advanced and metastatic disease. The addition of the tyrosine kinase inhibitor erlotinib prolongs median survival for only 2 weeks. While gemcitabine-based regimens are currently accepted as the standard first-line treatment of patients with locally advanced or metastatic pancreatic adenocarcinoma, there is no consensus regarding treatment in the second-line setting. It will not be untrue to say that there are no real medical breakthroughs with regards to improving the prognosis of pancreatic cancer as of 2011. On the other hand, we have made some progress in patients with advanced pancreatic neuroendocrine tumors. These patients have a 5-year survival that can range from 97% in benign insulinomas to as low as 30% in non-functional metastatic pancreatic neuroendocrine tumors. Treatment options may include surgery, transarterial chemoembolization of liver metastases, and cytotoxic therapy such as streptozotocin, 5-fluorouracil or doxorubicin. Somatostatin analogues, like octreotide, have been proven to prolong progression-free survival in patients with metastatic neuroendocrine tumors of midgut origin. In 2011, two targeted agents, a tyrosine kinase inhibitor sunitinib and mTOR inhibitor everolimus have been approved by FDA for pancreatic neuroendocrine tumors. With these approvals, U.S. physicians can now offer their patients with progressive pancreatic neuroendocrine tumors. Patients with any stage of pancreatic cancer should be considered candidates for clinical trials.

455 Editorial GLP-1-based therapies: the dilemma of uncertainty. 2011

Spranger, Joachim / Gundert-Remy, Ursula / Stammschulte, Thomas. · ·Gastroenterology · Pubmed #21723985.

ABSTRACT: -- No abstract --

456 Editorial Rac1 takes center stage in pancreatic cancer and ulcerative colitis: quantity matters. 2011

Wertheimer, Eva / Kazanietz, Marcelo G. · ·Gastroenterology · Pubmed #21704620.

ABSTRACT: -- No abstract --

457 Editorial Pancreatic cancer prevention and the 2010 Dietary Guidelines for Americans. 2011

Harris, Diane M / Srihari, Priya / Go, Vay Liang W. · ·Pancreas · Pubmed #21673534.

ABSTRACT: -- No abstract --

458 Editorial Idiopathic recurrent pancreatitis: an EUS-based management approach. 2011

Papachristou, Georgios I / Topazian, Mark. · ·Gastrointest Endosc · Pubmed #21628013.

ABSTRACT: -- No abstract --

459 Editorial Regional chemotherapy for pancreatic cancer. 2011

Avital, Itzhak. · ·J Surg Oncol · Pubmed #21618244.

ABSTRACT: -- No abstract --

460 Editorial HOX genes in pancreatic development and cancer. 2011

Gray, Sophie / Pandha, Hardev S / Michael, Agnieszka / Middleton, Gary / Morgan, Richard. · ·JOP · Pubmed #21546695.

ABSTRACT: The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity during development and which are subsequently re-expressed in many types of cancer. Some recent studies have shown that HOX genes may have key roles both in pancreatic development and in adult diseases of the pancreas, including cancer. In this review we consider recent advances in elucidating the role of HOX genes in these processes, how they may connect early developmental events to subsequent adult disease, and their potential both as diagnostic markers and therapeutic targets.

461 Editorial Pancreatic cancer surveillance: learning as we go. 2011

Brentnall, Teresa A. · ·Am J Gastroenterol · Pubmed #21540900.

ABSTRACT: The concept of pancreatic cancer prevention through surveillance of high-risk patients has come of age. It is cost-effective to provide surveillance of patients who have a lifetime risk of pancreatic cancer that is ≥16%. Studies are currently ongoing that contribute to our understanding of the imaging methodologies that are best suited for surveillance and the best algorithm for the clinical management of patients who are at risk of this highly lethal disease. Long-term outcomes analyses will help shed light on the best management of these patients, as well as a better understanding of the natural history of familial pancreatic cancer.

462 Editorial Emerging therapeutic targets and agents for pancreatic cancer therapy--where are we and where we have to go? 2011

Sebens, Susanne / Kalthoff, Holger. · ·Anticancer Agents Med Chem · Pubmed #21492077.

ABSTRACT: -- No abstract --

463 Editorial Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer. 2011

Grassetto, Gaia / Rubello, Domenico. · ·Am J Clin Oncol · Pubmed #21483236.

ABSTRACT: -- No abstract --

464 Editorial Walk closer or carry big glass? Comparing EUS and multidetector CT. 2011

Owens, Michael M. · ·Gastrointest Endosc · Pubmed #21457814.

ABSTRACT: -- No abstract --

465 Editorial 18F-FDG-PET/CT in the assessment of pancreatic cancer: is the contrast or a better-designed trial needed? 2011

Nguyen, Nam Q / Bartholomeusz, Dylan F. · ·J Gastroenterol Hepatol · Pubmed #21418296.

ABSTRACT: -- No abstract --

466 Editorial [Pancreatic cancer--association with diabetes mellitus and smoking]. 2011

Vavrecka, A. · ·Vnitr Lek · Pubmed #21416850.

ABSTRACT: -- No abstract --

467 Editorial MicroRNAs in pancreatic ductal adenocarcinoma. 2011

Park, Jong Y / Helm, James / Coppola, Domenico / Kim, Donghwa / Malafa, Mokenge / Kim, Seung Joon. · ·World J Gastroenterol · Pubmed #21412491.

ABSTRACT: Ductal adenocarcinoma of the pancreas is a lethal cancer for which the only chance of long-term survival belongs to the patient with localized disease in whom a potentially curative resection can be done. Therefore, biomarkers for early detection and new therapeutic strategies are urgently needed. miRNAs are a recently discovered class of small endogenous non-coding RNAs of about 22 nucleotides that have gained attention for their role in downregulation of mRNA expression at the post-transcriptional level. miRNAs regulate proteins involved in critical cellular processes such as differentiation, proliferation, and apoptosis. Evidence suggests that deregulated miRNA expression is involved in carcinogenesis at many sites, including the pancreas. Aberrant expression of miRNAs may upregulate the expression of oncogenes or downregulate the expression of tumor suppressor genes, as well as play a role in other mechanisms of carcinogenesis. The purpose of this review is to summarize our knowledge of deregulated miRNA expression in pancreatic cancer and discuss the implication for potential translation of this knowledge into clinical practice.

468 Editorial Three-drug combination regimen in pancreatic cancer treatment: are we there yet? 2011

Kang, Soonmo Peter / Saif, Muhammad Wasif. · ·JOP · Pubmed #21386625.

ABSTRACT: -- No abstract --

469 Editorial Adjuvant therapy for pancreatic cancer: a logical strategy in search of progress. 2011

Evans, Douglas B / Wolff, Robert A. · ·Ann Surg Oncol · Pubmed #21384245.

ABSTRACT: -- No abstract --

470 Editorial Timing is everything: Brca2 and p53 mutations in pancreatic cancer. 2011

Morton, Jennifer P / Steele, Colin W / Sansom, Owen J. · ·Gastroenterology · Pubmed #21352873.

ABSTRACT: -- No abstract --

471 Editorial Foreword: Gastroenteropancreatic system and its tumors: Part 2. 2011

LeRoith, Derek. ·Division of Endocrinology, Metabolism, and Bone Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. derek.leroith@mssm.edu ·Endocrinol Metab Clin North Am · Pubmed #21349407.

ABSTRACT: -- No abstract --

472 Editorial Pancreatic cancer. A multidisciplinary approach. 2011

López Martín, A / Carballo Alvarez, L F. · ·Rev Esp Enferm Dig · Pubmed #21341930.

ABSTRACT: -- No abstract --

473 Editorial [Pancreatic oncological surgery. Are the levels of excellence achievable?]. 2011

Sabater Ortí, Luis. · ·Cir Esp · Pubmed #21333973.

ABSTRACT: -- No abstract --

474 Editorial MiRegulators in cancer stem cells of solid tumors. 2011

Ma, Stephanie / Guan, Xin-Yuan. · ·Cell Cycle · Pubmed #21311235.

ABSTRACT: -- No abstract --

475 Editorial Promising advances in the treatment of malignant pancreatic endocrine tumors. 2011

Jensen, Robert T / Delle Fave, Gianfranco. · ·N Engl J Med · Pubmed #21306243.

ABSTRACT: -- No abstract --

Back · Next